- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Adherence and Time Spent Receiving IV Iron Infusions
Panelists discuss how IV iron formulations requiring fewer infusion visits tend to have better adherence rates, while the ongoing nursing shortage has created additional challenges in scheduling and administering IV iron treatments, leading clinicians to favor products that can achieve iron repletion in fewer sessions.
EP: 1.Background and Causes of Iron Deficiency Anemia
EP: 2.Pathophysiology of Iron Deficiency Anemia
EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia
EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia
EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis
EP: 6.Oral vs IV Iron in Clinical Practice
EP: 7.FDA-Approved IV Iron Formulations
EP: 8.Factoring in Safety Considerations With IV Iron Products
EP: 9.Adverse Effects Associated With Hypophosphatemia
EP: 10.Clinical Impact of Hypophosphatemia
EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron
EP: 12.Adherence and Time Spent Receiving IV Iron Infusions
EP: 13.Step Edits Associated with IV Iron Therapies
EP: 14.The Future of IV Iron Administration
EP: 15.Closing Thoughts on Iron Deficiency Anemia
Video content above is prompted by the following:
- Adherence to recommended treatment dosing tends to decline as the number of separate recommended infusion visits increases. Could you share your clinical experience on how variations in dosing among different agents influence patient adherence?
- Has the recent nursing shortage impacted your practice in patients requiring IV iron formulations?
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
